We are live on ! Find out more
GYRE icon

Gyre Therapeutics

28 hedge funds and large institutions have $796K invested in Gyre Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $708K → $796K (+$88.7K)

0.31% less ownership

Funds ownership: 0.71%0.4% (-0.31%)

26% less funds holding

Funds holding: 3828 (-10)

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Holders
28
Holders Change
-10
Holders Change %
-26.32%
% of All Funds
0.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
9
Closed
13
Calls
$28K
Puts
Net Calls
+$28K
Net Calls Change
+$10K
Name Holding Trade Value Shares
Change
Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$76
Wells Fargo
27
Wells Fargo
California
$67 +$4 +1 +8%
JP Morgan Chase
28
JP Morgan Chase
New York
$18
Millennium Management
29
Millennium Management
New York
-$56K -18,154 Closed
Bank of New York Mellon
30
Bank of New York Mellon
New York
-$41.5K -13,376 Closed
HF
31
HRT Financial
New York
-$16K -5,457 Closed
TSS
32
Two Sigma Securities
New York
-$10.5K -3,383 Closed
E
33
Ergoteles
New York
-$10.4K -3,354 Closed
Simplex Trading
34
Simplex Trading
Illinois
-$10.6K -2,962 Closed
BSW
35
Buckingham Strategic Wealth
Missouri
-$22.7K -2,873 Closed
Janney Montgomery Scott
36
Janney Montgomery Scott
Pennsylvania
-$8K -2,667 Closed
Goldman Sachs
37
Goldman Sachs
New York
-$4.43K -1,428 Closed
Citadel Advisors
38
Citadel Advisors
Florida
-$3.28K -1,057 Closed
AWA
39
Arete Wealth Advisors
Illinois
-$2K -690 Closed
ASN
40
Advisory Services Network
Georgia
-$207 -67 Closed

GYRE Hedge Fund Activity: Q2 2023 in Review

28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2023, worth a combined $796K — up 13% from $708K a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of GYRE and 3 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 3 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $11.6K. The largest seller was Millennium Management, exiting entirely with an estimated $56K sold.

  • 28 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2023, down from 38 in Q1 2023.
  • Funds reported $796K of Gyre Therapeutics stock for Q2 2023, up 13% quarter-over-quarter.
  • 3 funds opened new Gyre Therapeutics positions in Q2 2023 and 13 closed out, a net change of -10 holders.
  • The largest Gyre Therapeutics buyer in Q2 2023 was Virtu Financial, an estimated $11.6K added.
  • The largest Gyre Therapeutics seller in Q2 2023 was Millennium Management, an estimated $56K sold.

Based on aggregated 13F filings for Q2 2023.